Dyadic International (DYAI) Change in Interest Receivables (2018 - 2026)
Dyadic International (DYAI) posted Change in Interest Receivables of -$22706.0 for Q1 2026, down 2343.68% sequentially from $1012.0 in Q4 2025, and down 2093.82% YoY from $1138.8 in Q1 2025.
Dyadic International (DYAI) Change in Interest Receivables (2018 - 2026) Analysis & Trends
Dyadic International has reported Change in Interest Receivables for 9 years, with the latest figure at -$22706.0 in Q1 2026.
- Quarterly Change in Interest Receivables fell 2093.82% year-over-year to -$22706.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$10790.0 (down 235.11% YoY) and the FY2025 annual result came in at $10881.0, down 23.18% from the prior year.
- Change in Interest Receivables eased to -$22706.0 in Q1 2026 per DYAI's latest filing, from $1012.0 in the prior quarter.
- Over five years, Change in Interest Receivables peaked at $14412.0 in Q4 2022 and troughed at -$65481.0 in Q1 2022.
- A 5-year average of -$4820.7 and a median of $1012.0 in 2025 frame the typical range for Change in Interest Receivables.
- The widest YoY moves for Change in Interest Receivables: up 148.32% in 2024, down 6455.17% in 2024.
- Over 5 years, Change in Interest Receivables stood at $14412.0 in 2022, then slumped by 98.19% to $261.0 in 2023, then plunged by 6455.17% to -$16587.0 in 2024, then jumped by 106.1% to $1012.0 in 2025, then sank by 2343.68% to -$22706.0 in 2026.
- According to Business Quant data, Change in Interest Receivables over the past three periods registered -$22706.0, $1012.0, and -$619.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Interest Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Dyadic International | 19.98 Mn | 19.98 Mn | - | -22,706.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -22,706.00 |
| Dec 31, 2025 | 1,012.00 |
| Sep 30, 2025 | -619.00 |
| Jun 30, 2025 | 11,523.00 |
| Mar 31, 2025 | -1,035.00 |
| Dec 31, 2024 | -16,587.00 |
| Sep 30, 2024 | 12,675.00 |
| Jun 30, 2024 | 12,933.00 |
| Mar 31, 2024 | 5,144.00 |
| Dec 31, 2023 | 261.00 |
| Sep 30, 2023 | -26,231.00 |
| Jun 30, 2023 | 5,975.00 |
| Mar 31, 2023 | -28,207.00 |
| Dec 31, 2022 | 14,412.00 |
| Sep 30, 2022 | 1,636.00 |
| Jun 30, 2022 | 13,343.00 |
| Mar 31, 2022 | -65,481.00 |
| Dec 31, 2021 | 19,582.00 |
| Sep 30, 2021 | -88,520.00 |
| Jun 30, 2021 | -44.90 Mn |